Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dr. Vogelzang Describes Cabozantinib's Side Effects

June 21st 2011

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Vismodegib Trial Yields Benefits in BCC patients

June 20th 2011

Vismodegib has demonstrated positive overall response rates in patients with advanced basal cell carcinoma.

Dr. Vogelzang on Cabozantinib Clinical Trial Results

June 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Dr. Wolchok on Patients That Had to Stop Treatment Early

June 20th 2011

Dr. Jedd D. Wolchok From Memorial Sloan-Kettering Cancer Center on Patients That Had to Stop Treatment Early

Dr. Wolchok Explains the Future of Ipilimumab

June 17th 2011

Dr. Wolchok From Memorial Sloan-Kettering Cancer Center Explains the Future of Ipilimumab

Dr. Wolchok Describes Candidates for Ipilimumab

June 16th 2011

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes Candidates for Ipilimumab

Dr. Chapman on Vemurafenib Combination Therapies

June 16th 2011

Dr. Chapman from Memorial Sloan-Kettering Cancer Center on Vemurafenib Combination Therapies

Dr. Hoos Discusses Key Points of the Ipilimumab Trial

June 15th 2011

Dr. Hoos From Bristol-Myers Squibb Discusses Key Points of the Ipilimumab Trial

Dr. Chapman Describes Recent Melanoma Advances

June 15th 2011

Dr. Chapman From Memorial Sloan-Kettering Cancer Center Describes Recent Melanoma Advances

Dr. Chapman Describes the Vemurafenib Clinical Trial

June 10th 2011

Dr. Chapman From Memorial Sloan-Kettering Describes the Vemurafenib Clinical Trial

Dr. Infante on the Future of BRAF Inhibitors in Melanoma

June 8th 2011

Dr. Infante from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma

Two Studies Herald New Era in Melanoma Therapy

June 6th 2011

New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted

Dr. Wolchok Describes the Immunotherapy Ipilimumab

June 6th 2011

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab

MEK and BRAF Therapy Combo Promising for Advanced Melanoma

June 5th 2011

The combination of the MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 resulted in anti-tumor activity in patients with advanced melanoma

Dr. Hoos on the Patients That Respond to Ipilimumab

June 5th 2011

Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab

Dr. Chapman Describes the Side Effects of Vemurafenib

June 5th 2011

Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib

Tim Turnham Discusses Melanoma Treatment Advances

June 4th 2011

Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances

Dana Monroe Discusses Ipilimumab's Side Effects

June 2nd 2011

Dana Monroe from San Francisco Oncology Associates Discusses Ipilimumab's Side Effects

Experimental Melanoma Vaccine May Shrink Late-Stage Tumors

June 2nd 2011

An experimental melanoma vaccine gp100 peptide vaccine in combination with IL2 may shrink tumors and prevent the progression of late-stage melanoma

Vemurafenib Leads the Pack in new Melanoma Drugs, Research to be Presented at ASCO

May 31st 2011

Melanoma is now being treated with drugs and new treatment regimes that have shown great promise